APA (7 वां संस्करण) प्रशस्ति पत्र

(9618675), X. J., & (1776799), Z. L. (2025). Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: Based on the SONIA trial.docx.

शिकागो शैली (17वां संस्करण) प्रशस्ति पत्र

(9618675), Xiaohu Jin, और Zhifeng Li (1776799). Supplementary File 1_Cost-effectiveness Analysis of First-line Versus Second-line Use of CDK4/6 Inhibitors Combined with Endocrine Therapy in Advanced HR+/HER2- Breast Cancer in China: Based on the SONIA Trial.docx. 2025.

एमएलए (9वां संस्करण) प्रशस्ति पत्र

(9618675), Xiaohu Jin, और Zhifeng Li (1776799). Supplementary File 1_Cost-effectiveness Analysis of First-line Versus Second-line Use of CDK4/6 Inhibitors Combined with Endocrine Therapy in Advanced HR+/HER2- Breast Cancer in China: Based on the SONIA Trial.docx. 2025.

चेतावनी: ये उद्धरण हमेशा 100% सटीक नहीं हो सकते हैं.